Function of microRNA‑124 in the pathogenesis of cancer (Review)

Liu,Yuchen; Yang,Yipin; Wang,Xinyi; Yin,Siyue; Liang,Bingyu; Zhang,Yuchen; Fan,Min; Fu,Ziyue; Shen,Chuanlu; Han,Yanxun; Chen,Bangjie; Zhang,Qian

doi:10.3892/ijo.2023.5594

Function of microRNA‑124 in the pathogenesis of cancer (Review)

Authors:
- Yuchen Liu
- Yipin Yang
- Xinyi Wang
- Siyue Yin
- Bingyu Liang
- Yuchen Zhang
- Min Fan
- Ziyue Fu
- Chuanlu Shen
- Yanxun Han
- Bangjie Chen
- Qian Zhang
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China, First Clinical Medical College, Anhui Medical University, Hefei, Anhui 230000, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China, Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China, Second Clinical Medical College, Anhui Medical University, Hefei, Anhui 230000, P.R. China, Department of Pharmacy, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, Anhui 236000, P.R. China
Published online on: November 29, 2023 https://doi.org/10.3892/ijo.2023.5594
Article Number: 6
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑coding RNAs with a length of 22‑24 nt are known as microRNAs (miRNAs or miRs), which are critical regulators of protein translation. Over the past 10 years, the roles of miRNAs have been extensively investigated in several human cancer types. There is evidence to indicate that miRNAs regulate gene expression by concentrating on a number of substances that have an impact on the physiology and development of cancer cells. Thus, miRNAs as regarded as effective targets for further studies on the design of novel therapeutic strategies. Hepatocellular carcinoma, breast, prostate, and ovarian cancer are only a few of the cancers that miR‑124 suppresses. Furthermore, it has been shown that miR‑124 is linked to the development and aggressive spread of malignancies. The aim of the present review was to clarify and highlight the role of miR‑124 in the development and progression of cancer, emphasizing recent research illustrating how miR‑124 has been used as a therapeutic agent against cancer, as well as the diagnostic potential, regulatory mechanisms and clinical application of miR‑124.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.
2	Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR, Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 24:233–243. 2017.
3	Vineis P and Wild CP: Global cancer patterns: Causes and prevention. Lancet. 383:549–557. 2014.
4	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.
5	Basuroy R, Bouvier C, Ramage JK, Sissons M, Kent A and Srirajaskanthan R: Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 107:42–49. 2018.
6	Koo MM, Hamilton W, Walter FM, Rubin GP and Lyratzopoulos G: Symptom signatures and diagnostic timeliness in cancer patients: A review of current evidence. Neoplasia. 20:165–174. 2018.
7	Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R and Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 121:621–632. 2007.
8	Yan L, Xu F and Dai CL: Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Cancer Res. 37:2032018.
9	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016.
10	Roy PS and Saikia BJ: Cancer and cure: A critical analysis. Indian J Cancer. 53:441–442. 2016.
11	Wang JJ, Lei KF and Han F: Tumor microenvironment: Recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 22:3855–3864. 2018.
12	Okamoto A, Watanabe T, Kamata K, Minaga K and Kudo M: Recent updates on the relationship between cancer and autoimmune pancreatitis. Intern Med. 58:1533–1539. 2019.
13	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355
14	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993.
15	Asli NS, Pitulescu ME and Kessel M: MicroRNAs in organogenesis and disease. Curr Mol Med. 8:698–710. 2008.
16	Bueno MJ, Perez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle. 7:3143–3148. 2008.
17	Lu LF and Liston A: MicroRNA in the immune system, microRNA as an immune system. Immunology. 127:291–298. 2009.
18	Maatouk D and Harfe B: MicroRNAs in development. ScientificWorldJournal. 6:1828–1840. 2006.
19	Wang Y and Lee CG: MicroRNA and cancer-focus on apoptosis. J Cell Mol Med. 13:12–23. 2009.
20	Wu SG, Huang YJ, Bao B, Wu LM, Dong J, Liu XH, Li ZH, Wang XY, Wang L, Chen BJ and Chen W: miR-508-5p acts as an anti-oncogene by targeting MESDC1 in hepatocellular carcinoma. Neoplasma. 64:40–47. 2017.
21	Gao W, Li W, Xiao T, Liu XS and Kaelin WG Jr: Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/-clear cell renal carcinoma. Proc Natl Acad Sci USA. 114:1027–1032. 2017.
22	Xiao X, Tang C, Xiao S, Fu C and Yu P: Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res. 20:537–544. 2013.
23	Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu M, Li X and Tang H: MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 355:148–158. 2014.
24	Peng XH, Huang HR, Lu J, Liu X, Zhao FP, Zhang B, Lin SX, Wang L, Chen HH, Xu X, et al: MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer. 13:1862014.
25	Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR and Zhao Q: MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 34:713–722. 2013.
26	Yan G, Li Y, Zhan L, Sun S, Yuan J, Wang T, Yin Y, Dai Z, Zhu Y, Jiang Z, et al: Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5. Am J Cancer Res. 9:585–596. 2019.
27	Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T: Identification of tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
28	Clark AM, Goldstein LD, Tevlin M, Tavare S, Shaham S and Miska EA: The microRNA miR-124 controls gene expression in the sensory nervous system of Caenorhabditis elegans. Nucleic Acids Res. 38:3780–3793. 2010.
29	Zhou Q, Long L, Shi G, Zhang J, Wu T and Zhou B: Research of the methylation status of miR-124a gene promoter among rheumatoid arthritis patients. Clin Dev Immunol. 2013:5242042013.
30	Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M and Trimeche M: Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 35:4047–4056. 2014.
31	Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, Sugiyama T and Ushijima T: DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect. Int J Cancer. 124:2367–2374. 2009.
32	Gao C, Shen J, Meng ZX and He XF: Sevoflurane Inhibits Glioma cells proliferation and metastasis through miRNA-124-3p/ROCK1 axis. Pathol Oncol Res. 26:947–954. 2020.
33	Zhang TH, Liang LZ, Liu XL, Wu JN, Su K, Chen JY, Zheng QY, Huang HZ and Liao GQ: [Retracted] Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. Oncol Rep. 40:31122018.
34	Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, et al: MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 114:67–78. 2014.
35	Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 31:766–776. 2010.
36	Cao J, Qiu J, Wang X, Lu Z, Wang D, Feng H, Li X, Liu Q, Pan H, Han X, et al: Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-κB pathway. J Cancer. 9:3006–3015. 2018.
37	Zhou W, He L, Dai Y, Zhang Y, Wang J and Liu B: MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer. Exp Ther Med. 16:2811–2820. 2018.
38	Zo RB and Long Z: MiR-124-3p suppresses bladder cancer by targeting DNA methyltransferase 3B. J Cell Physiol. 234:464–474. 2018.
39	Zhou L, Xu Z, Ren X, Chen K and Xin S: MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating Rho-associated protein kinase 1(ROCK1). Cell Physiol Biochem. 38:1785–1795. 2016.
40	Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K and Akao Y: MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 363:17–27. 2015.
41	Yuan L, Li S, Zhou Q, Wang D, Zou D, Shu J and Huang Y: MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6. Oncol Lett. 14:7311–7317. 2017.
42	Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 32:4130–4138. 2013.
43	Gan H, Liu H, Zhang H, Li Y, Xu X, Xu X and Xu J: SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells. Tumour Biol. 37:9943–9950. 2016.
44	Smolewski P and Robak T: Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med. 11:633–649. 2011.
45	Frazzi R: BIRC3 and BIRC5: Multi-faceted inhibitors in cancer. Cell Biosci. 11:82021.
46	Jia X, Wang X, Guo X, Ji J, Lou G, Zhao J, Zhou W, Guo M, Zhang M, Li C, et al: MicroRNA-124: An emerging therapeutic target in cancer. Cancer Med. 8:5638–5650. 2019.
47	Tutar Y: miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 15:4292014.
48	Zhang L, Chen X, Liu B and Han J: MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer. Oncol Lett. 15:984–990. 2018.
49	Wu Q, Xu L, Wang C, Fan W, Yan H and Li Q: MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma. Biochem Biophys Res Commun. 503:2436–2442. 2018.
50	Yu B, Jiang K and Zhang J: MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-beta-mediated AKT/GSK-3beta/SNAIL-1 signaling. Mol Med Rep. 17:6736–6744. 2018.
51	Moghadasi M, Alivand M, Fardi M, Moghadam KS and Solali S: Emerging molecular functions of microRNA-124: Cancer pathology and therapeutic implications. Pathol Res Pract. 216:1528272020.
52	Wang P, Zhang LD, Sun MC, Gu WD and Geng HZ: Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells. Eur Rev Med Pharmacol Sci. 22:6308–6314. 2018.
53	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
54	Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 233:5574–5588. 2018.
55	Nagini S: Breast cancer: Current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 17:152–163. 2017.
56	Chen WY: Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab. 22:573–585. 2008.
57	Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 350:1655–1664. 2004.
58	Scully OJ, Bay BH, Yip G and Yu Y: Breast cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.
59	Li Z and Kang Y: Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 161:79–96. 2016.
60	Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, Li HY, Wu YM, Yan WJ and Xiao JR: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 17:92018.
61	Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang Y and Qi C: miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget. 7:16205–16216. 2016.
62	Yang W, Cui G, Ding M, Yang M and Dai D: MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer. J Clin Lab Anal. 34:e232662020.
63	Ji H, Sang M, Liu F, Ai N and Geng C: miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. Pathol Res Pract. 215:697–704. 2019.
64	Shi P, Chen C, Li X, Wei Z, Liu Z and Liu Y: MicroRNA-124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep. 19:3667–3675. 2019.
65	Sun Y, Li Q, Gui H, Xu DP, Yang YL, Su DF and Liu X: MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. Cell Res. 23:1270–1283. 2013.
66	Zhang Y, Li X, Zhang J and Liang H: Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis. Cancer Lett. 474:63–73. 2020.
67	Liu C, Xing H, Guo C, Yang Z and Wang Y and Wang Y: MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Cell Cycle. 18:2215–2227. 2019.
68	Yu X, Li Z, Zheng H, Chan MT and Wu WK: NEAT1: A novel cancer-related long non-coding RNA. Cell Prolif. 50:e123292017.
69	Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol. 233:8558–5866. 2018.
70	Pang Y, Wu J, Li X, Wang C, Wang M, Liu J and Yang G: NEAT1/miR-124/STAT3 feedback loop promotes breast cancer progression. Int J Oncol. 55:745–754. 2019.
71	Shi P, Liu Y, Yang H and Hu B: Breast cancer derived exosomes promoted angiogenesis of endothelial cells in microenvironment via circHIPK3/miR-124-3p/MTDH axis. Cell Signal. 95:1103382022.
72	Wang YF, Yu L, Hu ZL, Fang YF, Shen YY, Song MF and Chen Y: Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer. Cell Death Dis. 13:7482022.
73	Guo Q, Wang H, Duan J, Luo W, Zhao R, Shen Y, Wang B, Tao S, Sun Y, Ye Q, et al: An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer. Cancer Res. 82:4001–4015. 2022.
74	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.
75	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016.
76	Palmbos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins SA, et al: ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms. Cancer Res. 75:5155–5166. 2015.
77	Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H and Zietman AL: Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): A randomised multicentre phase 2 trial. Lancet Oncol. 14:863–872. 2013.
78	Girardi DM, Ghatalia P, Singh P, Iyer G, Sridhar SS and Apolo AB: Systemic therapy in bladder preservation. Urol Oncol. 41:39–47. 2023.
79	Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu S, Trump DL and Johnson CS: 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol. 148:166–171. 2015.
80	Wang S, Wu G, Han Y, Song P, Chen J, Wu Y, Yang J and Liang P: miR-124 regulates STAT3-mediated cell proliferation, migration and apoptosis in bladder cancer. Oncol Lett. 16:5875–5881. 2018.
81	Li T, Kang G, Wang T and Huang H: Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 16:687–702. 2018.
82	Annese T, Tamma R, Ruggieri S and Ribatti D: Erythropoietin in tumor angiogenesis. Exp Cell Res. 374:266–273. 2019.
83	Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y, Gu X and Meng F: MiR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1. FEBS J. 282:4376–4388. 2015.
84	Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, et al: Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 359:75–86. 2015.
85	Xiong Y, Wang L, Li Y, Chen M, He W and Qi L: The long non-coding RNA XIST interacted with MiR-124 to modulate bladder cancer growth, invasion and migration by targeting androgen receptor (AR). Cell Physiol Biochem. 43:405–418. 2017.
86	Lombard AP and Mudryj M: The emerging role of the androgen receptor in bladder cancer. Endocr Relat Cancer. 22:R265–R277. 2015.
87	Aguiar Junior S, Oliveira MM, Silva D, Mello CAL, Calsavara VF and Curado MP: Survival of patients with colorectal cancer in a cancer center. Arq Gastroenterol. 57:172–177. 2020.
88	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020.
89	Villeger R, Lopes A, Veziant J, Gagniere J, Barnich N, Billard E, Boucher D and Bonnet M: Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol. 24:2327–2347. 2018.
90	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017.
91	Kass SU, Pruss D and Wolffe AP: How does DNA methylation repress transcription? Trends Genet. 13:444–449. 1997.
92	Nakao M and Sasaki H: Genomic imprinting: Significance in development and diseases and the molecular mechanisms. J Biochem. 120:467–473. 1996.
93	Panning B and Jaenisch R: RNA and the epigenetic regulation of X chromosome inactivation. Cell. 93:305–308. 1998.
94	Yoder JA, Walsh CP and Bestor TH: Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13:335–340. 1997.
95	Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67:1424–1429. 2007.
96	Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, Zhao L, Ding J, Zhang L and Tang A: miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget. 6:38139–38150. 2015.
97	Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W and Yu T: Knockdown of Long Non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 51:113–128. 2018.
98	Zhang Y, Zheng L, Huang J, Gao F, Lin X, He L, Li D, Li Z, Ding Y and Chen L: MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One. 9:e939172014.
99	Xie XQ, Wang MJ, Li Y, Lei LP, Wang N, Lv ZY, Chen KL, Zhou B, Ping J, Zhou ZG and Sun XF: miR-124 intensified oxaliplatin-based chemotherapy by targeting CAPN2 in colorectal cancer. Mol Ther Oncolytics. 17:320–331. 2020.
100	Si M, Song Y, Wang X, Wang D, Liu X, Qu X, Song Z and Yu X: CXCL12/CXCR7/β-arrestin1 biased signal promotes epithelial-to-mesenchymal transition of colorectal cancer by repressing miRNAs through YAP1 nuclear translocation. Cell Biosci. 12:1712022.
101	Llovet JM, Montal R, Sia D and Finn RS: Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018.
102	Vaquero J, Guedj N, Claperon A, Nguyen Ho-Bouldoires TH, Paradis V and Fouassier L: Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J Hepatol. 66:424–441. 2017.
103	Wang H, Mao J, Huang Y, Zhang J, Zhong L, Wu Y, Huang H, Yang J, Wei Y and Tang J: Prognostic roles of miR-124-3p and its target ANXA7 and their effects on cell migration and invasion in hepatocellular carcinoma. Int J Clin Exp Pathol. 13:357–370. 2020.
104	Yue X, Cui Y, You Q, Lu Y and Zhang J: MicroRNA-124 negatively regulates chloride intracellular channel 1 to suppress the migration and invasion of liver cancer cells. Oncol Rep. 42:1380–1390. 2019.
105	Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289. 2012.
106	Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 27:7274–7284. 2008.
107	Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, et al: Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 12:419–431. 2007.
108	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
109	Chen G, Shi Y, Liu M and Sun J: circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma. Cell Death Dis. 9:1752018.
110	Agre P: The aquaporin water channels. Proc Am Thorac Soc. 3:5–13. 2006.
111	Magni F, Sarto C, Ticozzi D, Soldi M, Bosso N, Mocarelli P and Kienle MG: Proteomic knowledge of human aquaporins. Proteomics. 6:5637–5649. 2006.
112	Hu J and Verkman AS: Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 20:1892–1894. 2006.
113	Jablonski EM, Mattocks MA, Sokolov E, Koniaris LG, Hughes FM Jr, Fausto N, Pierce RH and McKillop IH: Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett. 250:36–46. 2007.
114	Chen XF, Li CF, Lu L and Mei ZC: Expression and clinical significance of aquaglyceroporins in human hepatocellular carcinoma. Mol Med Rep. 13:5283–5289. 2016.
115	Yu Q, Chen W, Li Y, He J, Wang Y, Yang S and Zhou J: The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered. 13:4717–4729. 2022.
116	Liang T, Wang Y, Jiao Y, Cong S, Jiang X, Dong L, Zhang G and Xiao D: LncRNA MALAT1 accelerates cervical carcinoma proliferation by suppressing miR-124 expression in cervical tumor cells. J Oncol. 2021:88360782021.
117	Wang Z, Li S and Zhang G: LncRNA DSCAM-AS1 negatively interacts with miR-124 to promote hepatocellular carcinoma proliferation. Crit Rev Eukaryot Gene Expr. 32:1–8. 2022.
118	Li J, Feng Q, Wei X and Yu Y: MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. Tumour Biol. 37:15221–15228. 2016.
119	Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, Tehfe M and Blais N: Management of stage III non-small cell lung cancer. Semin Oncol. 44:163–177. 2017.
120	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
121	Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg DA: Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143(5 Suppl): e314S–e40S. 2013.
122	Kaplan JA, Liu R, Freedman JD, Padera R, Schwartz J, Colson YL and Grinstaff MW: Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials. 76:273–281. 2016.
123	Deng XF, Jiang L, Liu QX, Zhou D, Hou B, Cui K, Min JX and Dai JG: Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: A meta-analysis. J Cardiothorac Surg. 11:282016.
124	Yang Q, Wan L, Xiao C, Hu H, Wang L, Zhao J, Lei Z and Zhang HT: Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer. Oncol Lett. 14:3429–3436. 2017.
125	Kim BN, Ahn DH, Kang N, Yeo CD, Kim YK, Lee KY, Kim TJ, Lee SH, Park MS, Yim HW, et al: TGF-β induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer. Sci Rep. 10:105972020.
126	Zu L, Xue Y and Wang J, Fu Y, Wang X, Xiao G, Hao M, Sun X, Wang Y, Fu G and Wang J: The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis. Carcinogenesis. 37:333–343. 2016.
127	Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 33:514–524. 2014.
128	Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ and Steenbergen RD: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 9:1672010.
129	Qi MM, Ge F, Chen XJ, Tang C and Ma J: MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3. Eur Rev Med Pharmacol Sci. 23:5242–5250. 2019.
130	Yu H, Chen Y and Jiang P: Circular RNA HIPK3 exerts oncogenic properties through suppression of miR-124 in lung cancer. Biochem Biophys Res Commun. 506:455–462. 2018.
131	Wu J, Weng Y, He F, Liang D and Cai L: LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and development of non-small-cell lung cancer. Anticancer Drugs. 29:628–636. 2018.
132	Li H, Guo X, Li Q, Ran P, Xiang X, Yuan Y, Dong T, Zhu B, Wang L, Li F, et al: Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells. Cancer Manag Res. 10:6599–6609. 2018.
133	Liu Y, Li L and Song XL: Exosomal circPVT1 derived from lung cancer promotes the progression of lung cancer by targeting miR-124-3p/EZH2 axis and regulating macrophage polarization. Cell Cycle. 21:514–530. 2022.
134	Kim K, Zang R, Choi SC, Ryu SY and Kim JW: Current status of gynecological cancer in China. J Gynecol Oncol. 20:72–76. 2009.
135	Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 95(Suppl 1): S161–S192. 2006.
136	Stewart C, Ralyea C and Lockwood S: Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156. 2019.
137	Zaman MS, Maher DM, Khan S, Jaggi M and Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 5:442012.
138	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007.
139	Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 105:7004–7009. 2008.
140	Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B and Canevari S: Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol. 42:1262–1272. 2010.
141	Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P and Calin GA: Epigenetic regulation of microRNAs in cancer: An integrated review of literature. Mutat Res. 717:77–84. 2011.
142	Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6:842013.
143	Deng X, Chen Y, Liu Z and Xu J: MiR-124-3p.1 sensitizes ovarian cancer cells to mitochondrial apoptosis induced by carboplatin. Onco Targets Ther. 13:5375–5386. 2020.
144	Chen L and Kong C: LINC00173 regulates polycystic ovarian syndrome progression by promoting apoptosis and repressing proliferation in ovarian granulosa cells via the microRNA-124-3p (miR-124-3p)/jagged canonical Notch ligand 1 (JAG1) pathway. Bioengineered. 13:10373–10385. 2022.
145	Siegel RL, Miller KD and Jemal A: Cancer statistics 2020. CA Cancer J Clin. 70:7–30. 2020.
146	Gomella LG, Petrylak DP and Shayegan B: Current management of advanced and castration resistant prostate cancer. Can J Urol. 21(2 Suppl 1): S1–S6. 2014.
147	Scher HI, Buchanan G, Gerald W, Butler LM and Tilley WD: Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 11:459–476. 2004.
148	Salinas CA, Tsodikov A, Ishak-Howard M and Cooney KA: Prostate cancer in young men: An important clinical entity. Nat Rev Urol. 11:317–323. 2014.
149	Han M, Partin AW, Pound CR, Epstein JI and Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 28:555–565. 2001.
150	Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX and Wang WC: MiR-124 suppresses cell motility and adhesion by targeting Talin 1 in prostate cancer cells. Cancer Cell Int. 15:492015.
151	Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ and deVere White RW: miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. Cancer Res. 75:5309–5317. 2015.
152	Yan K, Hou L, Liu T, Jiao W, Ma Q, Fang Z, Zhang S, Song D, Liu J, Gao X and Fan Y: lncRNA OGFRP1 functions as a ceRNA to promote the progression of prostate cancer by regulating SARM1 level via miR-124-3p. Aging (Albany NY). 12:8880–8892. 2020.
153	Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F and Soerjomataram I: The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 67:51–64. 2017.
154	Solomon B, Young RJ and Rischin D: Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 52:228–240. 2018.
155	Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis. 10:5402019.
156	Salazar C, Nagadia R, Pandit P, Cooper-White J, Banerjee N, Dimitrova N, Coman WB and Punyadeera C: A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell Oncol (Dordr). 37:331–338. 2014.
157	Yoshizawa JM and Wong DT: Salivary microRNAs and oral cancer detection. Methods Mol Biol. 936:313–324. 2013.
158	Lopez-Cortes A, Guerrero S, Redal MA, Alvarado AT and Quinones LA: State of art of cancer pharmacogenomics in Latin American Populations. Int J Mol Sci. 18:6392017.
159	Salazar-Ruales C, Arguello JV, Lopez-Cortes A, Cabrera-Andrade A, Garcia-Cardenas JM, Guevara-Ramirez P, Peralta P, Leone PE and Paz-Y-Miño C: Salivary MicroRNAs for Early detection of head and neck squamous cell carcinoma: A case-control study in the high altitude mestizo Ecuadorian population. Biomed Res Int. 2018:97927302018.
160	Zhao Y, Ling Z, Hao Y, Pang X, Han X, Califano JA, Shan L and Gu X: MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. Oncotarget. 8:25005–25020. 2017.
161	Yang S, Yuan ZJ, Zhu YH, Chen X and Wang W: lncRNA PVT1 promotes cetuximab resistance of head and neck squamous cell carcinoma cells by inhibiting miR-124-3p. Head Neck. 43:2712–2723. 2021.
162	Chen W, Yang J, Fang H, Li L and Sun J: Relevance function of Linc-ROR in the pathogenesis of cancer. Front Cell Dev Biol. 8:6962020.
163	Zare A, Ahadi A, Larki P, Omrani MD, Zali MR, Alamdari NM and Ghaedi H: The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol Biol Rep. 45:1587–1595. 2018.
164	Wu Q, Zhong H, Jiao L, Wen Y, Zhou Y, Zhou J, Lu X, Song X and Ying B: MiR-124-3p inhibits the migration and invasion of Gastric cancer by targeting ITGB3. Pathol Res Pract. 216:1527622020.
165	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006.
166	Clevers H and Nusse R: Wnt/beta-catenin signaling and disease. Cell. 149:1192–1205. 2012.
167	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004.
168	Dai J, Qian C, Su M, Chen M and Chen J: Gastrokine-2 suppresses epithelial mesenchymal transition through PI3K/AKT/GSK3β signaling in gastric cancer. Tumour Biol. 37:12403–12410. 2016.
169	Slomovitz BM and Coleman RL: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 18:5856–5864. 2012.
170	Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 17:989–997. 2012.
171	Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 5:921–929. 2005.
172	Parsons R: Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer. Clin Cancer Res. 11:7965–7966. 2005.
173	Hoesel B and Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 12:862013.
174	Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML and Sonenshein GE: Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res. 72:6268–6278. 2012.
175	Tobar N, Villar V and Santibanez JF: ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem. 340:195–202. 2010.
176	Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
177	Rudan I, Sidhu S, Papana A, Meng SJ, Xin-Wei Y, Wang W, Campbell-Page RM, Demaio AR, Nair H, Sridhar D, et al: Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis. J Glob Health. 5:0104092015.
178	Yar Saglam AS, Alp E, Elmazoglu Z and Menevse S: Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol. 35:526–543. 2016.
179	Saravanan S, Islam VI, Babu NP, Pandikumar P, Thirugnanasambantham K, Chellappandian M, Raj CS, Paulraj MG and Ignacimuthu S: Swertiamarin attenuates inflammation mediators via modulating NF-κB/IκB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. Eur J Pharm Sci. 56:70–86. 2014.
180	Wang Z, Li Y, Kong D, Ahmad A, Banerjee S and Sarkar FH: Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 292:141–148. 2010.
181	Kume T: Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenes Res. 1:82009.
182	Lu ML, Zhang Y, Li J, Fu Y, Li WH, Zhao GF, Li XH, Wei L, Liu GB and Huang H: MicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 23:121–136. 2019.
183	Lemieux E, Cagnol S, Beaudry K, Carrier J and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927. 2015.
184	Shahmohamadnejad S, Nouri Ghonbalani Z, Tahbazlahafi B, Panahi G, Meshkani R, Emami Razavi A, Shokri Afra H and Khalili E: Aberrant methylation of miR-124 upregulates DNMT3B in colorectal cancer to accelerate invasion and migration. Arch Physiol Biochem. 128:1503–1509. 2022.
185	Hernandez-Caballero ME, Sierra - Ramirez JA, Villalobos-Valencia R and Sesena-Mendez E: Potential of Kalanchoe pinnata as a cancer treatment adjuvant and an epigenetic regulator. Molecules. 27:64252022.
186	Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL III, Lee JJ, Tilghman SM, Gumbiner BM and Costantini F: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 90:181–192. 1997.
187	Duchartre Y, Kim YM and Kahn M: The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149. 2016.
188	Lang Q and Ling C: MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 426:247–252. 2012.
189	Napetschnig J and Wu H: Molecular basis of NF-kappaB signaling. Annu Rev Biophys. 42:443–468. 2013.
190	Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G and Scheidereit C: A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell. 40:63–74. 2010.
191	Xie C, Zhang LZ, Chen ZL, Zhong WJ, Fang JH, Zhu Y, Xiao MH, Guo ZW, Zhao N, He X and Zhuang SM: A hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in NF kappa B signaling and chemoresistance. Hepatology. 71:1660–1677. 2020.
192	Lv Y, Chen S, Wu J, Lin R, Zhou L, Chen G, Chen H and Ke Y: Upregulation of long non-coding RNA OGFRP1 facilitates endometrial cancer by regulating miR-124-3p/SIRT1 axis and by activating PI3K/AKT/GSK-3β pathway. Artif Cells Nanomed Biotechnol. 47:2083–2090. 2019.
193	Li Y, Zhang Z, Liu X, Huang T, He W, Shen Y, Liu X, Hong K and Cao Q: miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. Mol Cell Biochem. 388:219–231. 2014.
194	Yuan D, Zhu D, Yin B, Ge H, Zhao Y, Huang A, Wang X, Cao X, Xia N and Qian H: Expression of lncRNA NEAT1 in endometriosis and its biological functions in ectopic endometrial cells as mediated via miR-124-3p. Genes Genomics. 44:527–537. 2022.
195	Hu YZ, Hu ZL, Liao TY, Li Y and Pan YL: LncRNA SND1-IT1 facilitates TGF-beta1-induced epithelial-to-mesenchymal transition via miR-124/COL4A1 axis in gastric cancer. Cell Death Discov. 8:732022.
196	Jiang L, Lin T, Xu C, Hu S, Pan Y and Jin R: miR-124 interacts with the Notch1 signalling pathway and has therapeutic potential against gastric cancer. J Cell Mol Med. 20:313–322. 2016.
197	Xiao HJ, Ji Q, Yang L, Li RT, Zhang C and Hou JM: In vivo and in vitro effects of microRNA-124 on human gastric cancer by targeting JAG1 through the Notch signaling pathway. J Cell Biochem. 119:2520–2534. 2018.
198	Zheng YB, Xiao GC, Tong SL, Ding Y, Wang QS, Li SB and Hao ZN: Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 21:7197–7207. 2015.
199	Wu Z, Huang W, Chen B, Bai PD, Wang XG and Xing JC: Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol Sci. 21:2338–2345. 2017.
200	Qin Z and Liu X: miR-124, a potential therapeutic target in colorectal cancer. Onco Targets Ther. 12:749–751. 2019.
201	Zhou Z, Lv J, Wang J, Yu H, Lu H, Yuan B, Han J, Zhou R, Zhang X, Yang X, et al: Role of MicroRNA-124 as a prognostic factor in multiple neoplasms: A meta-analysis. Dis Markers. 2019:16547802019.
202	Jiao D, Li Z, Zhu M, Wang Y, Wu G and Han X: LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). Am J Cancer Res. 8:748–760. 2018.
203	Gao XR, Wang HP, Zhang SL, Wang MX and Zhu ZS: Pri-miR-124 rs531564 polymorphism and colorectal cancer risk. Sci Rep. 5:148182015.
204	Long HD, Ma YS, Yang HQ, Xue SB, Liu JB, Yu F, Lv ZW, Li JY, Xie RT, Chang ZY, et al: Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma. Mol Biol Rep. 45:2615–2623. 2018.
205	Cong C, Wang W, Tian J, Gao T, Zheng W and Zhou C: Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma. Cancer Biomark. 21:449–454. 2018.
206	Davis FG and McCarthy BJ: Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther. 1:395–401. 2001.
207	Chen T, Wang XY, Li C and Xu SJ: Downregulation of microRNA-124 predicts poor prognosis in glioma patients. Neurol Sci. 36:131–135. 2015.
208	Romero-Lopez MJ, Jimenez-Wences H, Cruz-De la Rosa MI, Roman-Fernandez IV and Fernandez-Tilapa G: miR-23b-3p, miR-124-3p and miR-218-5p synergistic or additive effects on cellular processes that modulate cervical cancer progression? A molecular balance that needs attention. Int J Mol Sci. 23:135512022.
209	Ruan F, Wang YF and Chai Y: Diagnostic values of miR-21, miR-124, and M-CSF in patients with early cervical cancer. Technol Cancer Res Treat. 19:15330338209149832020.
210	Liang F, Zhang H, Qiu Y, Xu Q, Jian K, Jiang L, Wang F and Lu X: MiR-124-5p inhibits the progression of gastric cancer by targeting MIEN1. Technol Cancer Res Treat. 19:15330338209791992020.
211	Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L and Xie L: miR-124-3p acts as a potential marker and suppresses tumor growth in gastric cancer. Biomed Rep. 9:147–155. 2018.
212	Wu DH, Liang H, Lu SN, Wang H, Su ZL, Zhang L, Ma JQ, Guo M, Tai S and Yu S: miR-124 suppresses pancreatic ductal adenocarcinoma growth by regulating monocarboxylate transporter 1-mediated cancer lactate metabolism. Cell Physiol Biochem. 50:924–935. 2018.
213	Zhang YH, Wang QQ, Li H, Ye T, Gao F and Liu YC: miR-124 radiosensitizes human esophageal cancer cell TE-1 by targeting CDK4. Genet Mol Res. 15:2016. View Article : Google Scholar
214	Gao C, Xu YJ, Qi L, Bao YF, Zhang L and Zheng L: CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol Toxicol. 38:825–845. 2022.
215	Hu D, Li M, Su J, Miao K and Qiu X: Dual-targeting of miR-124-3p and ABCC4 promotes sensitivity to Adriamycin in breast cancer cells. Genet Test Mol Biomarkers. 23:156–165. 2019.
216	Du J, He Y, Wu W, Li P, Chen Y, Hu Z and Han Y: Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. J Pharm Pharmacol. 71:196–205. 2019.
217	Wang L, Wu M and Zhou X: Long non-coding RNA UCA1 promotes retinoblastoma progression by modulating the miR-124/c-myc axis. Am J Transl Res. 14:1592–1605. 2022.
218	Qian C and Wang Y, Ji Y, Chen D, Wang C, Zhang G and Wang Y: Neural stem cell-derived exosomes transfer miR-124-3p into cells to inhibit glioma growth by targeting FLOT2. Int J Oncol. 61:1152022.
219	Gupta D, Zickler AM and El Andaloussi S: Dosing extracellular vesicles. Adv Drug Deliv Rev. 178:1139612021.
220	Lasser C, Eldh M and Lotvall J: Isolation and characterization of RNA-containing exosomes. J Vis Exp. 9:e30372012.
221	Barile L and Vassalli G: Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 174:63–78. 2017.
222	Isaac R, Reis FCG, Ying W and Olefsky JM: Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 33:1744–1762. 2021.
223	Groot M and Lee H: Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases. Cells. 9:10442020.
224	Shuang O, Zhou J, Cai Z, Liao L, Wang Y, Wang W and Xu M: EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA. J Orthop Surg Res. 17:3322022.
225	Bronisz A, Godlewski J and Chiocca EA: Extracellular vesicles and MicroRNAs: Their role in tumorigenicity and therapy for brain tumors. Cell Mol Neurobiol. 36:361–376. 2016.
226	Ma Y, Shen N, Wicha MS and Luo M: The roles of the Let-7 family of MicroRNAs in the regulation of cancer stemness. Cells. 10:24152021.
227	Masliah-Planchon J, Garinet S and Pasmant E: RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 7:38892–38907. 2016.
228	Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, et al: Ubiquitous release of Exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 76:7194–7207. 2016.
229	Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, Qin Y, Chen Y, Cui K, Zhou L, et al: Colorectal Cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages. Adv Sci (Weinh). 9:21026202022.
230	Urabe F, Kosaka N, Sawa Y, Yamamoto Y, Ito K, Yamamoto T, Kimura T, Egawa S and Ochiya T: miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1. Sci Adv. 6:eaay30512020.
231	Jiang F and Doudna JA: CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 46:505–529. 2017.
232	Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai JB, Zhang PF, Cui YH and Ke AW: Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 21:572022.
233	Horodecka K and Duchler M: CRISPR/Cas9: Principle, applications, and delivery through extracellular vesicles. Int J Mol Sci. 22:60722021.
234	Bao A, Burritt DJ, Chen H, Zhou X, Cao D and Tran LP: The CRISPR/Cas9 system and its applications in crop genome editing. Crit Rev Biotechnol. 39:321–336. 2019.
235	Chen M, Mao A, Xu M, Weng Q, Mao J and Ji J: CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett. 447:48–55. 2019.
236	Li W, Cho MY, Lee S, Jang M, Park J and Park R: CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition. PLoS One. 14:e02208602019.
237	Zhou SJ, Deng YL, Liang HF, Jaoude JC and Liu FY: Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. Cell Death Differ. 24:1577–1587. 2017.
238	Liu C, Ding X, Wei C, Pei Y, Meng F, Zhong Y and Liu Y: LncRNA LNCOC1 is Upregulated in melanoma and serves as a potential regulatory target of miR-124 to suppress cancer cell invasion and migration. Clin Cosmet Investig Dermatol. 15:751–762. 2022.
239	Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, et al: CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci. 232:1166362019.
240	Huo W, Zhao G, Yin J, Ouyang X, Wang Y, Yang C, Wang B, Dong P, Wang Z, Watari H, et al: Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J Cancer. 8:57–64. 2017.
241	Kunej T, Godnic I, Horvat S, Zorc M and Calin GA: Cross talk between microRNA and coding cancer genes. Cancer J. 18:223–231. 2012.
242	Hu S, Zang R, Wang Y, Liang Y, Mu J, Zhang Y and Ma J: Highly expressed microRNA-124 inhibits migration and promotes apoptosis of esophageal cancer cells by degrading PDCD6. J BUON. 24:805–812. 2019.
243	Zhao X, He W, Li J, Huang S, Wan X, Luo H and Wu D: MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354. 2015.
244	Liu Z, Guo S, Sun H, Bai Y, Song Z and Liu X: Circular RNA CircHIPK3 elevates CCND2 expression and promotes cell proliferation and invasion through miR-124 in Glioma. Front Genet. 11:10132020.
245	Sanuki R and Yamamura T: Tumor suppressive effects of miR-124 and its function in neuronal development. Int J Mol Sci. 22:59192021.
246	Yong T, Sun A, Henry MD, Meyers S and Davis JN: Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J Cell Biochem. 112:2340–2351. 2011.
247	Gao Y, Yang M, Wei L, Liang X, Wu F, Huang Y and Yang T: miR-34a-5p inhibits cell proliferation, migration and invasion through targeting JAG1/Notch1 pathway in HPV-infected human epidermal keratinocytes. Pathol Oncol Res. 26:1851–1859. 2020.
248	Cheng Z, Li X, Ye X, Yu R and Deng Y: Purpurogallin reverses neuronal apoptosis and enhances 'M2' polarization of microglia under ischemia via mediating the miR-124-3p/TRAF6/NF-kappaB axis. Neurochem Res. 48:375–392. 2023.
249	Wu Z, Huang W, Chen B, Bai PD, Wang XG and Xing JC: Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol Sci. 24:75462020.
250	Gao S, Yu J, Shan Z, Zuo L, Huang W, Gan L and Tian H: IncRNA XIST targets miR-124/JAG1 via CeRNA mechanism to facilitate the migration and proliferation of tongue squamous cell carcinoma. Clin Lab. 68:2022. View Article : Google Scholar
251	Guo W, Liu GM, Guan JY, Chen YJ, Zhao YZ, Wang K and Bai O: Epigenetic regulation of cutaneous T-cell lymphoma is mediated by dysregulated lncRNA MALAT1 through modulation of tumor microenvironment. Front Oncol. 12:9772662022.
252	Zhang WL, Zhao YN, Shi ZZ, Gu GY, Cong D, Wei C and Bai YS: HOXA11-AS promotes the migration and invasion of hepatocellular carcinoma cells by inhibiting miR-124 expression by binding to EZH2. Hum Cell. 32:504–514. 2019.
253	Ghafouri-Fard S, Shoorei H, Bahroudi Z, Abak A, Majidpoor J and Taheri M: An update on the role of miR-124 in the pathogenesis of human disorders. Biomed Pharmacother. 135:1111982021.